The Drug Discovery Market in 2026

Drug discovery is the front end of the pharmaceutical value chain: target identification, hit finding, lead optimisation and the preclinical work that turns a molecule into a candidate ready for human testing. As a standalone market it was valued at roughly $71.96 billion in 2025 and is forecast to reach about $78.61 billion in 2026, on track for around $174 billion by 2035 at a 9.24% CAGR (Towards Healthcare, 2026). That headline figure covers reagents, screening services, software and the outsourced discovery work that early-stage ventures both buy and sell.

The faster-growing slice is computational. The AI-in-drug-discovery sub-segment sat at roughly $3 to $6 billion in 2025 depending on scope, but it is compounding at 23% to 30% a year toward an estimated $160 billion by 2035 (Grand View Research, 2025). For a founder writing a plan today, that split matters: investors price an AI-first platform very differently from a services business, and your plan needs to declare which one you are on page one.

The structural story behind the numbers is cost compression. A new medicine has historically taken 12 to 15 years and an average of around $1.8 billion to reach the market when measured across a large pharma portfolio, yet a focused small biotech can advance a single asset for under $250 million (GEN, 2025). The companies attracting capital are the ones shaving time and money off the discovery phase. Insilico Medicine, Recursion and Exscientia have compressed candidate discovery from the industry-standard 2.5 to 4 years down to 9 to 18 months on some programmes. Your plan does not need that performance, but it does need a credible story about why your approach is cheaper, faster or more selective than the default.

The competitive set a new entrant must position against is unusually well known. Recursion Pharmaceuticals (phenomic screening, now combined with Exscientia), Insilico Medicine (generative chemistry), Schrödinger (physics-plus-machine-learning design), BenevolentAI (knowledge-graph repurposing) and Atomwise (structure-based virtual screening) define the platform tier. None of these is your direct competitor for a seed round, but every serious investor will ask how your method differs from theirs. The most fundable plans answer that in one sentence: a named modality, a named target class, and a reason the incumbents are not already there.

Three Ways to Build a Drug Discovery Business

The phrase "drug discovery business" hides three very different companies, and the first decision your plan must resolve is which one you are. Investors, grant assessors and bankers each underwrite these models on different terms, so a plan that blurs the line reads as unfocused. The table below maps the three archetypes on the dimensions that decide who funds you and how much they pay.

The services model is the most quietly fundable of the three and the one most founders overlook. A discovery CRO billing real clients has receivables a bank can lend against, a margin a buyer can value, and a track record that de-risks any later pivot into proprietary assets. The platform model is what venture capital chases, but only when there is a wedge: a named modality, a proprietary dataset, or a target class the incumbents have not cracked. The pure asset model raises the most per round and demands the most science, which is why it usually follows a partnership or a strong preclinical data package rather than starting cold.

A meaningful share of the strongest seed-stage plans we see deliberately blend the first two. They stand up a small services arm to generate cash and credibility, then route that cash and that reputation into a proprietary programme. The blended model is harder to explain in a single sentence, which is exactly why it needs a well-built plan: the financial model has to show the services revenue covering a defined slice of burn while the proprietary asset, which an investor is really buying, advances on schedule. Get that separation right and you can raise on better terms than a pure-asset peer, because you are diluting against a lower net burn.

Who Actually Buys, and Why

A drug discovery venture rarely sells to a patient. Depending on the model, the customer is a pharmaceutical or biotech company, a grant body, or an acquirer, and each buys on different criteria. The plan should name the priority buyer explicitly rather than gesturing at "the pharmaceutical industry," because the entire commercial strategy follows from that choice.

• Pharma and large biotech partners: the buyer for a platform or asset. They pay upfront fees, development milestones and royalties for access to a validated programme or a differentiated discovery engine. They buy de-risked science, clean IP and a team that can deliver to a contract.
• Other biotechs and academic groups: the buyer for a discovery CRO. They pay for capacity and specialist capability they do not have in house, on FTE or per-project terms. They buy speed, reliability and confidentiality.
• Grant bodies and non-dilutive funders: not customers in the usual sense, but they "buy" scientific merit and societal impact. NIH SBIR, Innovate UK and disease foundations fund the early science that makes the venture investable.
• Acquirers: the ultimate buyer for an asset venture. A pharma company acquiring a single de-risked programme is the most common exit, which is why the plan should name plausible acquirers and the data milestones that trigger their interest.

For each buyer, the plan should quantify the deal size, the sales cycle and the decision-maker. A pharma partnership can take twelve to eighteen months to negotiate and involve business development, scientific and legal review; a CRO contract can close in weeks but at a fraction of the value. Mapping this is not optional detail. It is how an investor judges whether your go-to-market matches your model, and it is one of the first things a sophisticated reader checks.

Quick Answers Founders Ask

These are the questions that come up in almost every first call about a drug discovery venture. Short answers here; the detail sits in the sections below.

Do you need a wet lab to start?

No. A large share of seed-stage ventures run virtual, outsourcing chemistry, assay development and screening to contract research organisations or buying cloud-lab time. That keeps the launch budget near the lower end. A wet lab buys control and turnaround speed but pushes capital into the millions and adds lease, instrument and biosafety overhead.

Is a drug discovery platform the same as a CRO?

No, and conflating the two is the fastest way to confuse an investor. A discovery CRO sells capability to clients and books revenue immediately. A platform creates proprietary assets it later licenses or develops, so it has higher upside and little early income. Many of the strongest early plans run a hybrid, with a small services arm funding a proprietary programme.

How long until there is a candidate?

Plan for 18 to 36 months from project start to a development candidate ready for IND-enabling studies, then another 12 to 18 months of toxicology and manufacturing work before a regulatory filing. Anything faster is a claim that needs evidence in the plan, not an assumption.

What It Costs to Launch

The honest answer is that drug discovery has no single startup number, because the three business models differ by an order of magnitude. A lean discovery-CRO or fully virtual venture that outsources its bench work can begin operating on roughly $350,000 to $750,000 (£280K to £600K). A wet-lab platform that owns instruments and intends to carry a programme to an IND filing typically needs $1.5 million to $4 million (£1.2M to £3.2M) of seed capital, because the IND-enabling study package alone runs $1M to $2.5M.

The variable that drives the spread is staff burn. Across the sector, an early-stage biotech burns roughly $20,000 per employee per month once salaries, benefits, consumables and overhead are counted (Experimental Designs Consulting, 2025). A ten-person team therefore needs about $2.4 million for a twelve-month runway, and most investors expect an eighteen-month plan with a 10% to 15% buffer on top. Your business plan lives or dies on whether the milestones you promise fit inside that runway.

Where the money goes

• Lab space, fume hoods, lease deposit and fit-out (or CRO bench fees): $60K–$600K (£48K–£480K)
• Core instruments - HTS, LC-MS, plate readers - or cloud-lab credits: $80K–$900K (£64K–£720K)
• Outsourced medicinal chemistry and assay development (CRO): $120K–$1.5M (£96K–£1.2M)
• IND-enabling toxicology and pharmacokinetic package (if reaching IND): $1M–$2.5M (£800K–£2M)
• Scientific salaries (~$20K per head per month burn): $240K–$1.2M/yr (£190K–£950K/yr)
• IP, patent filing and regulatory consulting: $40K–$200K (£32K–£160K)

The line founders most often underweight is the IND-enabling package. A regulatory submission for a small or large molecule commonly bundles 50 to 70 individual study reports (FDA, 2026), and the GLP toxicology, safety pharmacology and pharmacokinetic work behind them is the single biggest pre-clinical cost line. If your plan is to reach an IND, that number cannot be a placeholder. If your plan stops at a partnerable lead, say so clearly and let the partner carry that cost.

Lab & Platform Stack

Whether you build a wet lab or stay virtual, your plan should show that you know what the discovery engine actually needs. Below is the typical stack with indicative price ranges, so the operations and use-of-funds sections read as the work of someone who has scoped it.

• High-throughput screening (HTS) station or liquid handler: $40K–$250K - or rent capacity from a screening CRO per plate
• LC-MS / HPLC for compound characterisation: $80K–$350K new; refurbished units cut this by 40–60%
• Plate readers (fluorescence, luminescence, absorbance): $15K–$60K each
• Cell culture suite - incubators, biosafety cabinets, centrifuges: $30K–$120K
• Cold storage (-80°C freezers, liquid nitrogen): $8K–$25K per unit
• Compute and software - Schrödinger Maestro, OpenEye, RDKit, AlphaFold pipelines, cloud GPU credits: $20K–$300K/yr depending on licences
• ELN and data infrastructure - Benchling or Dotmatics: $5K–$50K/yr
• Cloud-lab option - Emerald Cloud Lab, Strateos: usage-based, replaces much of the above for virtual teams

For a virtual venture, the line items above mostly convert into CRO purchase orders and software subscriptions, which is exactly why the lean model can launch under $750K. The trade-off is turnaround: an in-house assay can iterate in days, while a CRO queue can run weeks. Your plan should make the chosen trade-off explicit rather than leaving an investor to wonder which one you picked.

How the Money Works

Drug discovery has three revenue archetypes, and a credible plan commits to one as the primary engine. The discovery-CRO model sells FTE contracts or day-rates, typically $8,000 to $25,000 per FTE-month, at 55% to 75% gross margin. The platform model earns through pharma partnership deals: upfront fees, development milestones and royalties on any drug that reaches the market. The asset model raises equity to create one or more proprietary molecules and earns nothing until partnering, acquisition or approval.

The single most common modelling error is putting a drug-sales line into a year-one to year-three forecast for an asset venture. There are no sales; there is a programme, a valuation step-up at each milestone, and a financing plan. Investors in this space read the burn rate, the runway and the next inflection point, not a revenue ramp. A platform plan should forecast partnership economics; an asset plan should forecast cash and milestones; only a services plan should forecast revenue in the conventional sense.

Partnership economics deserve their own treatment in a platform plan, because the headline numbers can mislead. A pharma deal is often quoted as a large total "biobucks" figure, but most of that value is contingent: a modest upfront payment, a series of milestone payments tied to development and regulatory progress, and royalties that only flow if a drug reaches the market years later. A credible forecast discounts those contingent payments by the probability of each milestone being hit, rather than booking the full headline value. Showing that you understand the difference between a $500 million deal on paper and the risk-adjusted cash it actually delivers is a strong signal to a sophisticated investor that the team can be trusted with their capital.

A worked example

Take an eight-person discovery venture burning the sector-typical ~$20K per head per month, which is roughly $1.92 million a year. To extend the runway without diluting further, the founders stand up a small fee-for-service arm billing three client FTEs in medicinal chemistry at $18,000 per FTE-month. That adds about $648,000 of annual revenue at roughly 60% gross margin, contributing close to $389,000 of gross profit toward burn. The proprietary kinase programme still consumes most of the cash, but the services line stretches a £1.6M seed from a fourteen-month to a roughly twenty-month runway, which is often the difference between a clean Series A and a down round. That is the hybrid logic many seed-stage platforms use, and it is the structure our paid plans model line by line.

Funding & Grant Routes

Drug discovery is rarely a clean fit for conventional small-business debt, because there is no near-term cash flow to service a loan. That said, US founders building the services or instrumentation side of a venture can use the SBA 7(a) programme, which lends up to $5M over terms as long as 25 years and is most useful for a discovery-CRO model with real receivables. NAICS 541714 (research and development in biotechnology, except nanobiotechnology) and 541715 are the codes lenders will use, and an SBA application will demand the same lender-ready financial forecast our bespoke service produces.

The larger non-dilutive pool for early discovery is grant funding. In the US, the NIH SBIR/STTR programmes provide up to roughly $314,000 in Phase I and $2M in Phase II for qualifying small businesses, and they do not take equity. In the UK, Innovate UK Biomedical Catalyst grants regularly back early discovery work, and the SEIS and EIS schemes give UK angel investors 50% and 30% income-tax relief respectively, which is why so many British discovery spin-outs raise their first £1M to £2M that way. Canada offers SR&ED tax credits; the EU runs Horizon Europe and EIC Accelerator grants. Your plan should layer these: grant capital de-risks the science, equity funds the burn, and the two together protect founder ownership.

Regulatory & Legal Path

Discovery work itself sits before the heavily regulated clinical phase, but your plan must show you understand the gate you are heading toward, because that gate sets the budget and timeline above. The three jurisdictions below are the ones most plans need to address.

United States

• Investigational New Drug (IND) application to the FDA before any first-in-human dosing; the FDA charges no IND filing fee but enforces a 30-day safety review before a trial may start
• IND-enabling GLP toxicology and safety pharmacology - the $1M–$2.5M package, often 50–70 study reports
• GMP manufacturing for the investigational product, with documented compliance in the IND dossier
• Institutional Animal Care and Use Committee (IACUC) approval for in-vivo studies
• Timeline: 18–36 months from candidate selection to IND submission depending on modality

United Kingdom

• Register and seek a Clinical Trial Authorisation (CTA) from the MHRA via the combined review route, alongside Research Ethics Committee approval
• Initial combined-review assessment is completed within 30 days; a final decision follows within 60 days of a valid application (GOV.UK / MHRA, 2026)
• The sponsor must be UK- or approved-country-based; an overseas founder must appoint a UK legal representative before submission
• GMP confirmation for any drug-product manufacturing location, and registration in a public trials database before recruitment
• Animal research requires a Home Office project licence under ASPA

European Union

• A single Clinical Trial Application through the EMA Clinical Trials Information System (CTIS) under Regulation 536/2014, valid across member states
• Compliance with EU GMP and the centralised pharmacovigilance framework

The practical takeaway for a discovery-stage plan is sequencing. You are not filing an IND on day one, but the cost and timeline of that filing should already be visible in your milestones so that an investor sees the full path, not just the part you can afford this year.

Operations, Team & Milestones

Capital follows credibility, and in drug discovery credibility is concentrated in two things: the team and the milestone plan. A plan that nails the science but leaves operations vague will stall in diligence, so this section should read as the work of people who have actually run a programme.

The team an investor expects to see

A seed-stage discovery venture is usually built around a scientific founder with deep domain expertise and a complementary operator who can run a budget and a fundraise. Beyond the founders, the early hires that matter most are a medicinal or computational chemist, an assay biologist, and a part-time or fractional regulatory and quality lead. A scientific advisory board of two or three respected names in the target area does more for a seed pitch than another junior hire, because it signals that experienced scientists have already vetted the thesis. The plan should name these roles, show when each is hired against the runway, and be honest about which capabilities are outsourced to a CRO rather than built in house.

The milestone plan that unlocks the next round

Discovery capital is released against scientific inflection points, not calendar dates, so the operations plan should be a milestone map. A typical seed-to-Series-A sequence runs: target validation, hit identification, hit-to-lead, lead optimisation, then candidate selection. Each step changes the company's valuation, and each should have a defined budget and a defined deliverable in the plan. The single most important number is the cost and timing of the milestone that justifies the next round. If your seed funds you to candidate selection, the plan must show that candidate selection lands inside the runway with cash to spare, because raising while you are out of money is how good science gets financed on bad terms.

How the venture reaches its buyers

Go-to-market in this sector is relationship-led, not advertising-led. Platform and asset ventures reach pharma partners through business-development conferences such as BIO and JP Morgan Healthcare, through scientific publications and conference posters that establish the data, and through warm introductions from advisors and investors. A discovery CRO, by contrast, can build a more conventional pipeline: inbound enquiries from a strong technical website, referrals from satisfied clients, and targeted outreach to biotechs that lack a given capability. The plan should match the channel to the model. A CRO with a credible sales motion and a platform with a credible partnering motion are fundable; a venture that confuses the two is not.

Mistakes That Sink the Raise

Across the discovery-stage plans we review, the same five errors come up. Each one is avoidable, and each one is the kind of thing an experienced life-sciences investor spots in the first ten minutes.

• Forecasting drug sales in years 1–3. An asset venture has no product revenue for years. A sales ramp where there should be a milestone plan tells the investor you do not understand the model.
• Underbudgeting the IND-enabling package. The $1M–$2.5M toxicology and manufacturing line is the largest pre-clinical cost. Leaving it vague signals the plan was written from a template, not from the science.
• Pitching a broad AI platform with no lead. "We use machine learning across all of drug discovery" funds nothing. A named target class and a lead programme funds rounds. The incumbents already own "general platform"; you need a wedge.
• Ignoring the UK sponsor and legal-representative rule. Overseas founders planning a UK trial routinely miss that the sponsor must be UK-based or appoint a UK legal representative, which derails the timeline late.
• Choosing asset creation when services would fund the team. Many founders would be far more investable launching a discovery-CRO first, building cash and credibility, then spinning out a proprietary programme. The plan should defend the model choice, not assume it.

Key Terms, Defined

• Target: the biological molecule (often a protein) a drug is designed to act on.
• Hit: a compound that shows activity against the target in an early assay.
• Lead optimisation: chemically refining a hit into a candidate with the right potency, selectivity and safety profile.
• IND (Investigational New Drug): the FDA submission that allows first-in-human testing to begin.
• GLP / GMP: Good Laboratory Practice for safety studies and Good Manufacturing Practice for producing the investigational product.
• CRO: contract research organisation; an outsourced provider of discovery, preclinical or clinical services.
• Burn rate: monthly net cash outflow; in early biotech, roughly $20K per employee.
• Milestone payment: a sum a pharma partner pays when a programme hits an agreed scientific or regulatory step.

Sample Business Plan Preview

Here is an extract from a drug discovery business plan written by our team, so you can see the level of specificity investors in this sector expect:

What's in the Template

Every Avvale business plan template is pre-structured for your industry. For drug discovery, that means the sections are tuned to what life-sciences investors and grant assessors actually read:

• Executive Summary - model type (platform, asset or CRO), lead programme, target class and the ask, in under a page
• Company & Science Overview - founding team, IP position, and the scientific thesis in plain language
• Market Analysis - discovery-market and AI sub-segment sizing, with the competitive tier named
• Pipeline & Programme Plan - milestones from target to candidate to IND, mapped to the runway
• Operations Plan - wet-lab versus virtual decision, CRO partners, and the platform stack
• Regulatory Strategy - IND, CTA and CTIS pathways and the sequencing of the filing
• Use of Funds - burn-rate-driven budget tied to scientific inflection points
• Management Team - founder and advisor bios, scientific advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with burn-rate scheduling, runway analysis, milestone-linked financing, grant layering and the lender-ready output an SBA, SEIS or EIS process requires. For a closely related model, see our biotech drug discovery business plan template, the pharmaceutical drug development template, and the clinical diagnostics template. You can also browse the full library of free business plan templates.

Frequently Asked Questions